Today: 19 May 2026
Browse Category

NASDAQ:NVAX 6 November 2025 - 8 May 2026

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax Stock Jumps As Pfizer Deal Cash Puts Vaccine Turnaround Back In Focus

Novavax shares jumped 13% Friday after first-quarter revenue reached $139.5 million, beating estimates. Licensing and partner payments, including $30 million from Pfizer’s Matrix-M deal, offset weak COVID-19 vaccine demand. The stock traded at $10.45 with volume over 8.4 million shares. Investors await the company’s appearance at BofA’s health-care conference on May 13.
8 May 2026
···
Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax, Inc. Stock Jumps: Why Pfizer’s Matrix-M Deal Drove a Surprise Q1 Revenue Beat

Novavax reported first-quarter revenue of $139.5 million, beating analyst expectations but down sharply from $666.7 million a year earlier. Licensing and partner payments, including $30 million from Pfizer, offset weak COVID-19 vaccine demand. Shares rose 1.7% Thursday after a 15.6% jump Wednesday, with trading volume spiking to 16.5 million shares. Product sales fell to $42.2 million, while licensing and other revenue reached $97.3 million.
7 May 2026
··
Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax Stock Jumps as Pfizer Vaccine Deal Drives Big Q1 Revenue Beat

Novavax reported first-quarter revenue of $139.5 million, beating estimates as licensing and partner payments, including $30 million from Pfizer, offset weak COVID-19 vaccine sales. Shares rose 15.6% to $9.36 in afternoon trading. Product sales dropped to $42.2 million from $621.7 million a year ago. The company maintained its 2026 adjusted revenue forecast of $230 million to $270 million.
6 May 2026
··
Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax stock drops 6% into the weekend as Pfizer Matrix‑M cash and earnings clock loom

Novavax shares fell 6.4% to $8.85 at Friday’s close, underperforming the broader market. Trading volume topped 5 million shares, above the 50-day average. Investors are watching for updates on partner-driven cash, including a $30 million upfront payment expected in Q1 2026 from a license deal. Novavax delayed its profitability target to 2028 and projects 2026 adjusted revenue of $185–$205 million.
31 January 2026
····
Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer stock price edges up — what PFE investors are watching after vaccine policy shifts

Pfizer shares closed up 0.8% at $26.10 Thursday, trading between $25.75 and $26.31. The gain followed news of a non-exclusive deal with Novavax for access to its Matrix‑M adjuvant, worth $30 million upfront. U.S. officials have reversed universal vaccine recommendations, shifting to “shared clinical-decision-making.” Pfizer CEO Albert Bourla blamed policy rhetoric for falling vaccination rates.
23 January 2026
···
Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer (PFE) stock edges up as ViiV exit cash and Novavax vaccine-tech pact grab attention

Pfizer shares rose 0.8% to $25.73 Wednesday after the company agreed to exit its ViiV Healthcare stake, with Shionogi paying $1.875 billion and raising its holding to 21.7%. Pfizer also secured rights to Novavax’s Matrix-M adjuvant for $30 million upfront. Both deals await regulatory clearance and do not guarantee near-term earnings growth. Investors await Pfizer’s Q4 results on Feb. 3.
21 January 2026
····
NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

NVAX Stock Today: Can Novavax Turn Regulatory Turmoil and Activist Pressure into a Comeback?

Novavax (NASDAQ: NVAX) closed at $6.91 on December 5, 2025, with a market cap near $1.1 billion. Shares are down about 20% over the past year and 94% over five years. Q2 2025 saw a surprise profit on $239 million revenue, boosted by a $175 million Sanofi milestone payment, but Q3 revenue dropped to $70 million with a net loss of $202 million. The stock trades 40% below its January high.
7 December 2025
Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax Stock (NVAX) on November 24, 2025: Price, Sanofi Deal, Shah Capital Pressure and What It All Means for Investors

Novavax (NASDAQ: NVAX) closed at $6.47 on Friday, up 4.0% but still 44% below its 52-week high. Q3 revenue beat estimates at $70 million, though losses widened and profitability is now targeted for 2028. Shah Capital is pressuring for a sale and threatening a proxy fight. The company expanded its Sanofi partnership, securing $225 million in milestones this year.
24 November 2025
·
Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax (NVAX) Raises 2025 Revenue Outlook After Q3 Beat; Sanofi Milestones Drive Guidance — November 6, 2025

Novavax raised its FY2025 adjusted revenue outlook to $1.04–$1.06 billion after reporting Q3 revenue of $70 million, above estimates. The company posted a GAAP net loss of $202 million for the quarter, impacted by $126 million in non-cash charges tied to Maryland site consolidation and debt. Two $25 million milestone payments from Sanofi will be recognized in Q4. Cash stood at $778 million as of September 30.
6 November 2025
·····

Stock Market Today

  • Polymarket Teams with Nasdaq Private Market to Launch Private Company Prediction Contracts
    May 19, 2026, 4:47 PM EDT. Polymarket has launched a new category of prediction markets for private companies in collaboration with Nasdaq Private Market, enabling trading on pre-IPO company events like funding rounds and valuations. This innovation aims to boost price discovery in typically opaque private markets. Polymarket's move targets the growing number of unicorns-startups valued over $1 billion-with nearly 1,600 globally. The partnership signals increasing institutional interest in prediction markets tied to private equity amid improving regulatory support and market infrastructure. Despite this, retail investors currently drive 80% of prediction market volume, according to a recent Bitget Wallet and Polymarket report. This development could enhance transparency and forecasting in private capital markets, drawing more professional engagement.

Latest articles

Google Stock Slips as Alphabet’s $5 Billion AI Cloud Bet Faces Wall Street’s New Test

Google Stock Slips as Alphabet’s $5 Billion AI Cloud Bet Faces Wall Street’s New Test

19 May 2026
Alphabet Class A shares fell 2.3% to $387.66 Tuesday after Google announced new Gemini AI models, paid subscription tiers, and a $5 billion Blackstone-backed AI cloud venture. The stock had traded as high as $401.71 intraday. Google also cut prices on its top AI subscription plans and introduced Gemini 3.5 Flash, but the stronger 3.5 Pro model remains unreleased.
Nvidia Earnings Date Locked In as Wall Street Awaits AI Stock Moves

Nvidia Earnings Date Locked In as Wall Street Awaits AI Stock Moves

19 May 2026
Nvidia will report fiscal first-quarter earnings after markets close Wednesday, with analysts expecting revenue near $79 billion, up almost 80% from a year ago. Options traders are pricing a 6.5% one-day move in Nvidia shares, or about $355 billion in market value. Shares closed Tuesday at $220.61, valuing the company at $5.4 trillion. Investors are watching for guidance on AI data center spending and competition in AI chips.
NextNRG shares double as buying spikes, but the numbers show a catch

NextNRG shares double as buying spikes, but the numbers show a catch

19 May 2026
NextNRG shares more than doubled Tuesday, closing at $0.8288 and rising to about $0.91 after hours, after reporting April revenue up 56% to $9.4 million, its highest on record. Gross margin for April reached 8.3%. Trading volume topped 344 million shares, with market value near $135 million. The company posted a first-quarter net loss of $10.8 million and had $208,048 in cash at March 31.
Go toTop